Biology & Source
HMSC-derived exosomes are nanoscale extracellular vesicles (30–150nm) secreted by human mesenchymal stem cells, carrying growth factors, immunomodulatory microRNA, neurotrophic proteins, and angiogenic mediators. Unlike whole-cell therapies, they deliver biological cargo without transferring genetic material or living cells.
Verified donor HMSCs from Wharton's Jelly (umbilical cord). Early-passage, xeno-free culture. All donors undergo a 14-pathogen viral screening panel.
CD9/CD63/CD81 tetraspanins; EGF, FGF, VEGF, IGF-1, TGF-β growth factors; miR-21, miR-146a; BDNF, GDNF; Wnt pathway modulators; IL-10, TSG-6; angiogenic mediators.
The therapeutic properties of an exosome are entirely determined by the cell that produced it. High-passage or mischaracterised cells produce different cargo. BEXO publishes batch data because source integrity is the most important and most frequently unverified variable in commercial exosome products.
Quality & Testing
NTA (particle count/size), TEM (morphological confirmation), ELISA tetraspanin panel (CD9/CD63/CD81), RNA sequencing (miRNA cargo profile), 14-pathogen viral screen, USP <71> sterility, LAL endotoxin assay (<0.1 EU/mL post-reconstitution), ambient stability verification across full 12-month shelf life. See the full QC panel explained.
Full COA with every shipment, batch-level traceability, scientific reference pack, formulation protocol documentation, dedicated account manager.
GMP-certified production means the facility adheres to regulated quality management systems, environmental controls, process validation, and full batch documentation. Not universal in the commercial exosome market - its absence significantly increases risk of product inconsistency and uncharacterised contamination. Read more about GMP manufacturing for exosome biologics.
Products & Format
ExoPearls™ use a patented cryo-sphere process: exosomes are precision-dropped into liquid nitrogen forming solid 3–4mm spheres, locking cargo in a stable amorphous matrix without freeze-drying stress. Lyophilisation can compromise lipid bilayer integrity and cargo bioavailability. ExoPearls™ dissolve instantly in saline with zero cryoprotectant additives, activity verified across 12 months. Learn more about ExoPearl™ technology.
BEXO·CORE: 2-sphere vial, ≥20×10&sup9; total, topical/intradermal/scalp, research/cosmetic grade.
BEXO·PRIME: 20-sphere vial, ≥200×10&sup9; total, IV administration, licensed physicians only.
BEXO·NEURO: triple concentration ≥30×10&sup9;/sphere, enriched miR-21/miR-146a/BDNF/GDNF cargo, IV/intranasal, specialist access.
View full product catalogue →
Yes. No animal-derived components (including foetal bovine serum) are used at any stage of cell culture or manufacturing.
Regulatory
No. ExoPearls™ are investigational research-grade biologics, not approved by FDA, EMA, TGA, or any authority. Not marketed as treatments. US supply is research-only. Practitioners assume full regulatory responsibility.
Products intended for therapeutic use fall under the ATMP (Advanced Therapy Medicinal Products) framework regulated by the EMA. BEXO products are supplied as research-grade biologics or cosmetic-grade raw material actives, outside the ATMP therapeutic framework. Practitioners are responsible for jurisdiction-specific compliance.
Supply under TGA Special Access Scheme (SAS) or Authorised Prescriber (AP) framework. Cosmetic topical products compliant for direct supply.
Ordering & Logistics
Track A (Professional): licensed physicians, specialists, registered clinics apply for direct wholesale accounts, verified within 48 hours.
Track B (Individual): patients connected with a verified Partner Practitioner in their region.
See full details on the global access page.
No minimum order quantity. Volume discounts available. Wholesale pricing issued on account activation.
Ambient stable for 12 months - no cold chain, dry ice, or special packaging required. Ships worldwide via standard international courier from Hong Kong SAR.
Clinical Evidence
IV/Longevity: CHEST 2023 Phase 2 RCT - 30.8% absolute risk reduction in ARDS mortality, zero treatment-related adverse events (n=102). NIH meta-analysis 2024: 0.7% SAE rate across all EV trials globally.
Hair Regeneration: PMC Systematic Review 2025 (11 studies, 2 RCTs) - 9.5–35 hairs/cm² density gain, up to 13μm thickness improvement, no serious adverse events.
Neurology: Frontiers in Cellular Neuroscience 2024 - MSC exosomes promote neuroplasticity and recovery in TBI/stroke models.
Pain: PMC Clinical Review 2024 - 65% BPI severity reduction, 72% interference reduction, 58% ODI improvement at 3 months (n=20, zero adverse events).
For full references, see the scientific evidence page and clinical evidence review.
NIH 2024 meta-analysis: 0.7% SAE rate across all completed EV clinical trials globally. CHEST 2023 Phase 2 RCT: zero treatment-related adverse events. PMC 2025 alopecia review: no serious adverse events across all included studies. PMC 2024 pain review: zero adverse events in epidural cohort.